Breaking News

CPhI Report Addresses Battle Between Innovators and Biogenerics

Regulation shifting due to increased data dependence, regulatory oversight is slowing six sigma, forecasts generic growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CPhI Worldwide has released the findings of part III of its annual report  focused on the immediate and long-term trends in pharmaceutical data, regulation, generics and biosimilars. The report includes contributions from four experts in data, regulation, generics and biosimilars: Dilip G. Shah, Alan Sheppard, Bikash Chatterjee, and Ajaz S. Hussain.   The overall findings warn that the FDA’s approach to achieving six sigma is currently failing, encouraging regulatory oversight, rather than the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters